HomeComparePSCIX vs JNJ

PSCIX vs JNJ: Dividend Comparison 2026

PSCIX yields 6.47% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PSCIX wins by $110.59M in total portfolio value
10 years
PSCIX
PSCIX
● Live price
6.47%
Share price
$10.02
Annual div
$0.65
5Y div CAGR
73.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$110.62M
Annual income
$98,380,167.26
Full PSCIX calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — PSCIX vs JNJ

📍 PSCIX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSCIXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSCIX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PSCIX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSCIX
Annual income on $10K today (after 15% tax)
$549.96/yr
After 10yr DRIP, annual income (after tax)
$83,623,142.17/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, PSCIX beats the other by $83,619,104.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSCIX + JNJ for your $10,000?

PSCIX: 50%JNJ: 50%
100% JNJ50/50100% PSCIX
Portfolio after 10yr
$55.33M
Annual income
$49,192,458.57/yr
Blended yield
88.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

PSCIX
No analyst data
Altman Z
4.8
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSCIX buys
0
JNJ buys
0
No recent congressional trades found for PSCIX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSCIXJNJ
Forward yield6.47%2.14%
Annual dividend / share$0.65$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR73.3%28%
Portfolio after 10y$110.62M$30.5K
Annual income after 10y$98,380,167.26$4,749.88
Total dividends collected$109.64M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PSCIX vs JNJ ($10,000, DRIP)

YearPSCIX PortfolioPSCIX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,821$1,121.26$10,594$274.49+$1.2KPSCIX
2$14,796$2,146.77$11,294$360.69+$3.5KPSCIX
3$20,183$4,351.78$12,133$476.91+$8.1KPSCIX
4$31,211$9,614.72$13,156$635.42+$18.1KPSCIX
5$57,476$24,080.58$14,432$854.61+$43.0KPSCIX
6$133,323$71,823.40$16,056$1,162.76+$117.3KPSCIX
7$412,491$269,835.53$18,175$1,604.53+$394.3KPSCIX
8$1,793,514$1,352,148.69$21,009$2,252.68+$1.77MPSCIX
9$11,441,096$9,522,036.34$24,911$3,229.73+$11.42MPSCIX
10$110,622,140$98,380,167.26$30,458$4,749.88+$110.59MPSCIX

PSCIX vs JNJ: Complete Analysis 2026

PSCIXStock

The investment seeks income and, secondarily, absolute returns. The fund seeks primarily to implement a convertible arbitrage strategy by investing in convertible securities, including convertible preferred securities, and establishing short positions, or hedges, in the common stock of the issuers of the convertible securities. It may also use other instruments to establish hedges, including exchange-traded funds ("ETFs"), options and currency forwards, as appropriate, to reduce unwanted exposures. The fund may have significant exposure to the Financial sector.

Full PSCIX Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this PSCIX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSCIX vs SCHDPSCIX vs JEPIPSCIX vs OPSCIX vs KOPSCIX vs MAINPSCIX vs ABBVPSCIX vs MRKPSCIX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.